Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

Golshid Saki1,2, Akram Eidi3, Pejman Mortazavi4, Negar Panahi5, Akbar Vahdati1,2

1Department of Biology, Fars Science and Research Branch, Islamic Azad University, Fars, Iran
2Department of Biology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
3Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
4Department of Pathology, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
5Department of Basic Sciences, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

Submitted: 4 July 2017
Accepted: 28 July 2017

Arch Med Sci 2020; 16 (3): 699–706
DOI: https://doi.org/10.5114/aoms.2020.94659
Copyright © 2019 Termedia & Banach

Abstract

Introduction: β-Asarone is a major component of Acorus tatarinowii Schott. It has pharmacological effects that include antihyperlipidemic, anti-inflammatory, and antioxidant activity. In the present study, the effect of β-asarone on neurodegeneration induced by intrahippocampal administration of β-amyloid was investigated in adult male Wistar rats.

Material and methods: The rats were randomly divided into 9 groups: normal control, sham-operated control, β-asarone (12.5, 25, and 50 mg/kg intragastrically, daily) alone, Alzheimeric control rats (β-amyloid, intrahippocampal), β-asarone (12.5, 25, and 50 mg/kg intragastrically, daily) together with β-amyloid, and treatment was performed accordingly. Animals were injected with β-amyloid bilaterally. Animals received β-asarone daily using an intragastric tube for 50 days, starting from 30 days before administration of the β-amyloid. The rats were sacrificed and parameters of oxidative stress, superoxide dismutase (SOD) and glutathione peroxidase (GPX) activity were measured in hippocampus homogenate. Histopathological changes were examined by Bielschowsky staining.

Results: Our results showed that administration of β-asarone (25 and 50 mg/kg) significantly increased the levels of antioxidant enzymes, including SOD (1.09 ±0.02, 1.21 ±0.02, p < 0.001, respectively) and GPX (58.94 ±3.64, 68.92 ±3.64, p < 0.001, respectively) in comparison with Alzheimeric control rats (SOD and GPX level for Alzheimeric control group: 0.44 ±0.01, 35.09 ±1.15, respectively). Histopathological examination showed that β-asarone decreased cell loss in the cerebral cortex and hippocampus in Alzheimeric rats.

Conclusions: These results indicate that β-asarone is effective in providing protection against oxidative stress and neuronal damage induced by β-amyloid.

Key words: β-asarone, β-amyloid, neurodegeneration, rat.

Introduction

β-Asarone (cis-2,4,5-trimethoxy-1-allyl phenyl), which can affect the central nervous system [1–4], is a major component of Acorus tatarinowii Schott. β-Asarone could pass the blood-brain barrier (BBB) and thus enter the brain [5]. Pharmacological studies have demonstrated that β-asarone
not only has nootropic and neuroprotective effects [6–11], but also has a cardiovascular protective effect [12, 13], so we supposed that it might provide cerebrovascular protection, decrease cerebral hypoperfusion and hypometabolism and treat Alzheimer’s disease (AD). Recent studies have suggested that β-asarone has anti-apoptosis activity [8, 9, 11, 14]. Moreover, β-asarone is effective against experimental models of AD [9–10, 14, 15], cerebral ischemia [16], ischemia-reperfusion-induced autophagy [17], oxygen-glucose deprivation, reperfusion-induced injury [18], and epilepsy [19].

AD is the most common form of dementia and affects millions of people worldwide. The characteristic features associated with AD patients include loss of memory-associated neurons, especially cholinergic neurons, resulting in the neurotransmitter imbalance and synaptic dysfunction [20, 21]. The pathophysiology of AD is associated with a variety of factors, including extracellular deposition of insoluble β-amyloid protein aggregates, forming senile plaques and intracellular accumulation of neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau proteins, oxidative neuronal damage, and inflammatory cascades [22–24]. Current treatments provide only a modest benefit against clinical worsening [25, 26], so there is considerable interest in identifying new treatments for AD. The objective of this study was to investigate the effect of β-asarone on neurodegeneration induced by intrahippocampal administration of β-amyloid in adult male Wistar rats.

Material and methods

Chemicals

β-amyloid and β-asarone were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). Assay kits for superoxide dismutase (SOD) and glutathione peroxidase (GPX) were purchased from Randox (Crumlin, UK). All other reagents used in this study were of analytical grade. Solutions of the drugs and chemicals were freshly prepared before use.

Animals

Male Wistar rats, initially weighing 200 to 250 g, were used in this study. The animals were housed in groups of 5 per cage in a room with controlled temperature (22 ±2°C), lighting (on, 7 AM; off, 7 PM), and relative air humidity (40–60%). The animals had free access to standard laboratory chow and tap water. The diet was purchased from Pars-Dam food service, Tehran, Iran. Experimental procedures involving the animals and their care were conducted according to institutional guidelines, which are in accordance with the national and international laws and the Guidelines for Care and Use of Laboratory Animals in Biomedical Research, as adopted and distributed by the World Health Organization (WHO) and the United States National Institutes of Health 1985, no. 85-23. The experimental protocol was approved by the Research and Ethics Committee of the College of Science, Islamic Azad University.

Intrahippocampal injection of β-amyloid

β-amyloid was dissolved in DMSO to 5 mM exactly as described in the publication of Fa et al. [27]. Then 5 mM β-amyloid was diluted with sterile (1×) PBS to 100 µM on the day before surgery. The solution was mixed well by trituration and β-amyloid solution was incubated for 12 h at 4°C. Animals were anesthetized with ketamine hydrochloride (100 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.). The head was placed in position in the stereotaxic apparatus and a midline sagittal incision was made in the scalp. The stereotaxic coordinates for the CA1, hippocampus [28] were measured accurately as anterio-posterior – 3.0 mm, lateral 2.25 mm and dorso-ventral, 2.8 mm ventral from the surface of the brain. The β-amyloid was prepared and slowly infused (1 µl/min) by Hamilton microsyringe in a volume of 2 µl into CA1 of the hippocampus bilaterally. Rats in the sham-operated group received an injection of the same volume of diluting DMSO in PBS [29].

Experimental design

β-Asarone was dissolved in corn oil and given orally once daily by an orogastric tube for 50 days, starting from 30 days before administration of the β-amyloid. The rats were randomly divided into 9 experimental groups of 12 animals each as follows:

- group I: Normal control rats received 1 ml of corn oil as vehicle intragastrically.
- group II: Sham-operated control rats that underwent surgery. The animals received vehicle of β-amyloid (2 µl) in CA1 of the hippocampus bilaterally and were given 1 ml of corn oil intragastrically.
- groups III–V: Normal rats received β-asarone (12.5, 25, and 50 mg/kg bw) daily using an intragastric tube for 50 days.
- group VI: Alzheimer’s control rats were administered β-amyloid in a volume of 2 µl in CA1 of the hippocampus bilaterally. The animals received corn oil intragastrically, as vehicle for 20 days.
- groups VII–IX: Alzheimeric rats received β-asarone (12.5, 25, and 50 mg/kg bw) daily using an intragastric tube for 50 days, starting from 30 days before administration of the β-amyloid. The oral administration volume was 1 ml. The animals were carefully monitored daily.

Biochemical analysis

At the end of the experiment, the animals (6 animals of each group) were anesthetized by...
inhalation of diethyl ether. The entire brain was then extracted and the hippocampus was dissected and used for biochemical studies. The hippocampuses were washed with chilled saline and then homogenized in chilled phosphate buffer (pH 7.4). The homogenates were centrifuged at 800 × g for 5 min at 4°C to separate the nuclear debris. The supernatant was centrifuged at 10,500 × g for 20 min at 4°C, which was used to assay GPX and SOD activities.

SOD activity was measured according to the directions of the kit. A competitive inhibition assay was done using xanthine-xanthine oxidase-generated O$_2^-$ to reduce nitroblue tetrazolium (NBT) to blue formazan. One unit of SOD activity was determined as the amount of enzyme necessary to reduce NBT to 50% of the maximum. The maximum absorbance was read at 550 nm and the enzyme activity was expressed as units/mg protein [30].

GPX activity was measured by the method based on the reaction between GSH remaining after the action of GPX and 5,5-dithiobis-2-nitrobenzoic acid to form a complex with the maximal absorbance at 412 nm. One unit of GPX activity was defined as a 1 mol/l per min decrease in GSH in an enzymatic reaction using 1 mg of protein per min, deducting the effect of nonenzyme-catalyzed reaction [31].

**Histopathological examination**

At the end of the experiment, the animals (6 animals of each group) were anesthetized by inhalation of diethyl ether and perfused transcardially through the ascending aorta with 100 ml of ice cold phosphate buffered saline (PBS 0.1 M, pH 7.4) followed by 4% paraformaldehyde in cold PBS (0.1 M pH 7.4). The cortex and hippocampus were used for histological studies. The brain was post fixed in the paraformaldehyde solution for 48 h. After fixation, the tissue was dehydrated and embedded in paraffin. Coronal sections were assessed at 1.8–2.0 mm rostral to the optic chiasma. Sections (4 µm) were prepared and subjected to Bielschowsky staining as described in the protocol of the instructions. After staining, the stained hippocampus and cortex sections were examined under a light microscope (Nikon E200, Japan). Neuronal cell count with Image Analyzer version 1.36.1 software in the cortex, CA1, CA2, CA3 and dentate gyrus of the hippocampus was done.

**Statistical analysis**

Statistical analyses were carried out using the SPSS 10 (SPSS, Chicago, Ill) program for Windows. Data were expressed as mean ± SEM. Data were analyzed by one-way analysis of variance followed by Tukey’s post hoc test. The criterion for statistical significance was $p < 0.05$.

**Results**

In the present study, we successfully created an experimental Alzheimeric model in rats without any mortality. Our results showed that treatment with β-asarone (12.5, 25, and 50 mg/kg bw) caused no toxicity symptoms, and there was no record of death.

**Biochemical findings**

GPX and SOD activities in the hippocampus homogenates are shown in Figures 1 and 2. GPX and SOD activities in hippocampus homogenates...
of the Alzheimer’s control group were found to be significantly lower than those in the sham-operated and normal control group \((p < 0.001)\). Administration of the rats with \(\beta\)-asarone at doses of 25 and 50 mg/kg increased the activities of both enzymes compared to the Alzheimic control rats \((p < 0.001)\). No significant alteration was seen in normal control rats treated only with \(\beta\)-asarone (Figures 1 and 2).

**Histopathological findings**

Bielschowsky staining was used to detect histomorphological changes in cerebral cortex and hippocampal neurons following \(\beta\)-amyloid administration (Figure 3). In Alzheimic control rats, Bielschowsky staining revealed cell loss and neuronal necrosis with accumulation of astrocytes as gliosis, NFTs and neuritic plaques in the cerebral cortex. There are on average 3 neuritic plaques in each high power field (HPF). In addition, there are on average 12 NFTs in HPF in the cortex and the hippocampus. Neuronal loss, especially in the CA1 area, was seen in the hippocampus of the Alzheimer’s control rats. Compared to the Alzheimer’s control rats, administration of \(\beta\)-asarone at 25 and 50 mg/kg increased the number of surviving neurons and decreased NFTs (Figure 3). Our results

![Figure 3](image-url)

Figure 3. Bielschowsky staining in cerebral cortex and CA1 region of hippocampus. Cerebral cortex in normal control group (A) showed normal neuronal cell body (arrow) and vessels (arrowhead). CA1 of hippocampus in normal control group (B) showed normal neuronal cell (arrowhead) population. Sham-operated group in (C) revealed normal neuron (arrowhead) in the cortex. Normal rats administered \(\beta\)-asarone at doses of 12.5 (D), 25 (E), and 50 (F) mg/kg revealed a normal neuronal cell body (arrowhead)
Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

Figure 3. Cont. Alzheimer’s control group revealed neuritic plaques (arrow) in cerebral cortex (G) and in CA1 (H). Also, loss of neuronal cell population (arrow) and neurofibrillary tangles (arrowhead) was seen. β-asarone at dose of 12.5 mg/kg (I) led to moderate neurofibrillary tangles (arrowhead) and neuronal necrosis (arrow) in Alzheimeric rats. Administration of β-asarone at doses of 25 (J), 50 (L) mg/kg revealed few neurofibrillary tangles (arrow) in cortex, improved neuronal population (arrowhead) and decreased neuronal necrosis (arrow) in CA1 (K, M)
Table I. Effect of β-asarone at doses of 12.5, 25, and 50 mg/kg bw on neuron numbers in normal and Alzheimeric rats

| Groups                                      | Neuron numbers          |
|---------------------------------------------|-------------------------|
|                     | Cortex | CA1 | CA2 | CA3 | Dentate gyrus |
| Group I (Normal control)                   | 83.50 ±2.17            | 125.16 ±0.83 | 53.66 ±1.33 | 75.00 ±1.32 | 192.5 ±2.11 |
| Group II (sham-operated control)           | 85.66 ±1.65            | 125.16 ±0.60 | 51.83 ±1.52 | 74.16 ±0.94 | 193.33 ±0.79 |
| Group III (Normal + β-asarone (12.5 mg/kg))| 81.00 ±1.18            | 124.66 ±0.84 | 49.00 ±1.68 | 74.83 ±2.21 | 191.83 ±1.38 |
| Group IV (Normal + β-asarone (25 mg/kg))   | 78.66 ±1.35            | 120.83 ±0.75 | 49.00 ±2.21 | 72.83 ±1.38 | 193.66 ±1.38 |
| Group V (Normal + β-asarone (50 mg/kg))    | 82.00 ±1.71            | 126.00 ±1.57 | 51.5 ±1.46 | 72.16 ±1.01 | 187.33 ±4.15 |
| Group VI (Alzheimeric control)             | 38.16 ±1.30***         | 42.16 ±1.45*** | 42.4 ±1.03*** | 55.66 ±1.63*** | 93.16 ±1.97*** |
| Group VII (Alzheimeric + β-asarone (12.5 mg/kg)) | 45.16 ±2.14***       | 53.83 ±1.14*** | 46.83 ±0.60** | 59.60 ±1.09*** | 107.83 ±1.88*** |
| Group VIII (Alzheimeric + β-asarone (25 mg/kg)) | 69.33 ±1.80******     | 109.17 ±2.52**** | 48.33 ±0.86* | 71.83 ±1.35** | 182.33 ±1.61**** |
| Group IX (Alzheimeric + β-asarone (50 mg/kg)) | 80.16 ±2.70****       | 123.00 ±1.41*** | 49.33 ±1.26** | 75.00 ±1.16*** | 187.83 ±1.70**** |

*The number of neurons in ten fields in each area is counted. Values are expressed as mean ± SEM for six rats. *p < 0.05, **p < 0.01, ***p < 0.001 significantly different from the normal control group. +p < 0.05, ++p < 0.01, +++p < 0.001 significantly different from the Alzheimeric control group.

showed that the number of neurons was normal in the cerebral cortex and hippocampus. Also, our findings showed cell loss in these zones after administration of β-amyloid in rats. Administration of β-asarone at doses of 25 and 50 mg/kg significantly decreased cell loss in the cerebral cortex and hippocampus (Table I).

Discussion

In the present study, we found that β-asarone dose-dependently increased activities of GPX, and SOD, and attenuated brain architecture damage in Alzheimeric rats. Based on our data, administration of β-asarone caused histological and biochemical improvements in Alzheimeric rats. There were no significant alterations in normal rats treated with β-asarone.

It has previously been demonstrated that infusion of β-amyloid in rats resulted in significant decrease of the antioxidant capacity [32, 33]. Oxidative stress and related degeneration of cholinergic neurons is one of the most common sharing pathways involved in neurodegenerative disorders such as AD [34–36]. The brain is more susceptible to reactive oxygen species (ROS)-mediated injury because its cellular membranes are preferentially enriched in oxyradical-sensitive polyunsaturated fatty acids that are the substrates of lipid peroxidation. It has also been reported in earlier reports that AD brains exhibit a marked increase in malondialdehyde (MDA) and nitrite levels and decreased activity of endogenous antioxidant enzymes such as glutathione, catalase, and SOD [37–39]. During oxidative stress, β-amyloid can pass through the neuronal membrane bilayer and induce overproduction of ROS. Moreover, SOD and GPX are the two main antioxidant enzymes involved in cellular protection against damage induced by free radicals [40]. Levels of both have been shown to be decreased in the brains of patients with AD [41, 42]. Therefore, measurements of the activity of antioxidant enzymes are important when comparing the alterations induced by β-amyloid with those found in AD patients. In our study, β-amyloid alone-treated rats exhibited a decrease of SOD and GPX activity in the hippocampal homogenates.

Furthermore, our results showed that β-asarone (25 and 50 mg/kg bw) increased the activity of SOD and GPX in the hippocampal homogenates of β-amyloid-treated rats. The present study supports the hypothesis that β-asarone possesses strong antioxidant properties. β-asarone can exert neuroprotective effects in both in vivo and in vitro AD models [8, 10, 11]. Our previous study proved that β-asarone could reduce neuronal apoptosis and improve memory deficits in AD-model mice [14]. It is reported that β-asarone could protect cerebral ischemia via increasing antioxidants activity. β-asarone could pass the BBB and is well distributed in the brain [5, 43, 44]. Other investigators have shown that β-asa-
Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

β-asarone is capable of protecting cultured cortical neurons from glutamate toxicity [6, 45]. Pharmacological studies have demonstrated that β-asarone not only has nootropic and neuroprotective effects [6–9, 11, 46], but also has a cardiovascular protective effect [12, 13], so it is supposed that it might provide cerebrovascular protection, decrease cerebral hypoperfusion and hypometabolism and treat AD.

Our results showed that intrahippocampal administration of β-amyloid decreased the number of neurons in both the hippocampus and cortex. Also, β-amyloid caused extensive injuries, characterized by moderate to severe neuronal degeneration and necrosis. NFTs and accumulation of astrocytes in the form of gliosis were observed. However, our results showed that the brain lesions induced by intrahippocampal administration of β-amyloid were significantly reduced in rats that received concomitant β-asarone. Neurodegeneration in AD is associated with oxidative stress, dysfunction of mitochondria, impaired energy metabolism, progressive β-amyloid agglutination, and formation of NFTs [47]. The effectiveness of β-asarone in this β-amyloid model of dementia also indicates the possible antioxidant activity of β-asarone, since the β-amyloid model is predominantly based on free radical production [48].

In this study, toxicokinetic study of β-asarone in the blood of animals administered β-asarone was not performed. This would provide other information regarding the kinetic of this compound in rats and potentially could help to correlate the Tmax with the dosage, histopathology findings, and/or SOD/GPX measurements. Also, other organs and tissues have not been evaluated histopathologically and by the clinical pathology assessment to investigate potential toxicity of this compound in other organs such as the heart, liver, kidney, and lymphoid tissues.

In conclusion, the present results demonstrate that β-amyloid induces memory impairments in rats, while β-asarone treatment significantly improves biochemical and neuronal histopathology parameters in Alzheimeric rats.

Conflict of interest

The authors declare no conflict of interest.

References

1. Chen YZ, Wang QW, Liang Y, Fang YQ. Protective effects of β-asarone on cultured rat cortical neurons damage induced by glutamate. Zhong Yao Cai 2007; 30: 436-8.
2. Cho J, Ho KY, Kong JY. Protection of cultured rat cortical neurons from excitotoxicity by asarone, a major essential oil component in the rhizomes of Acorus gramineus. Life Sci 1998; 71: 591-9.
3. Fang YQ, Fang RM, Fang GL, Jiang Y, Fu SY. Effects of beta-asarone on expression of c-fos in kindling epilepsy rat brain. Zhongguo Zhong Yao Za Zhi 2008; 33: 534-6.
4. Fang YQ, Li L, Wu QD. Effects of beta-asarone on gene expression in mouse brain. Zhong Yao Cai 2003; 26: 650-2.
5. Fang YQ, Wei G. To analyze if the Rhizoma Acori Tatarinowii naphtha can go through the BBB or not with GC-MS. Zhong Yao Xin Yao Yu: Ling Chuang Yao Li 2002; 3: 181-2.
6. Cho J, Kim YH, Kong JY, Yang CH, Park CG. Protection of cultured rat cortical neurons from excitotoxicity by asarone, a major essential oil component in the rhizomes of Acorus gramineus. Life Sci 2002; 71: 591-9.
7. Chun HS, Kim JM, Choi EH, Chang N. Neuroprotective effects of several Korean medicinal plants traditionally used for stroke remedy. J Med Food 2008; 11: 246-51.
8. Geng Y, Li C, Liu J, et al. Beta-asarone improves cognitive function by suppressing neuronal apoptosis in the beta-amyloid hippocampus injection rats. Biol Pharm Bull 2010; 33: 836-43.
9. Li C, Xing G, Dong M, et al. Beta-asarone protection against beta-amyloid-induced neurotoxicity in PC12 cells via JNK signaling and modulation of Bcl-2 family proteins. Eur J Pharmacol 2010; 635: 96-102.
10. Liu J, Li C, Xing G, et al. Beta-asarone attenuates neuronal apoptosis induced by beta amyloid in rat hippocampus. Yakugaku Zasshi 2010; 130: 737-46.
11. Zou DJ, Wang G, Liu JC, et al. Beta-asarone attenuates beta-amyloid-induced apoptosis through the inhibition of the activation of apoptosis signal-regulating kinase 1 in SH-SYSY cells. Pharmacol 2011; 46: 44-51.
12. Qiduan WU, Qinghe WU, Qiwen W, Yuzhi C. Study on anti-thrombosis effect of volatile oil of Acorus Tatarinowii Schott and b-asarone. Zhong Yao Xin Yao Yu Lin Chuang Yao Li 2008; 19: 29-31.
13. Yi-zhi C, Ruo-ming F, Gang W, et al. Effect of volatile oil of Acorus and b-Asarone on vasomotion and anti-platelet aggregation in rats with hyperlipidemia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004; 24: 16-8.
14. Wei G, Chen YB, Chen DF, et al. Beta Asarone inhibits neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in an in vitro model and AbetaPP/PS1 mice. J Alzheimers Dis 2013; 33: 863-80.
15. Li Z, Zhao G, Qian S, et al. Cerebrovascular protection of beta-asarone in Alzheimer’s disease rats: a behavioral, cerebral blood flow, biochemical and genic study. J Ethnopharmacol 2012; 144: 305-12.
16. Yang YX, Chen YT, Zhou XJ, Hong CL, Li CY, Guo JY. Beta-asarone, a major component of Acorus tatarinowii Schott, attenuates focal cerebral ischemia induced by middle cerebral artery occlusion in rats. BMC Complement Altern Med 2013; 13: 236.
17. Liu L, Fang YQ, Xue ZF, He YP; Fang RM, Li L. Beta-asarone attenuates ischemia-reperfusion-induced autophagy in rat brains via modulating JNK, pJNK, Bcl-2 and Beclin 1. Eur J Pharmacol 2012; 680: 34-40.
18. Mo ZT, Fang YQ, He YP; Zhang S. Beta-Asarone protects PC12 cells against OGD/R-induced injury via attenuating Beclin-1-dependent autophagy. Acta Pharmacol Sin 2012; 33: 737-42.
19. Fu SY, Fang RM, Fang GL, Xie YH, Fang YQ. Effects of beta-asarone on expression of FOS and GAD65 in cortex of epileptic rat induced by penicillin. Zhong Yao Cai 2008; 31: 79-81.
20. St George-Hyslop PH. Piecing together Alzheimer’s. Sci Am 2000; 283: 76-83.
21. Monczor M. Diagnosis and treatment of Alzheimer's disease. Curr Med Chem Cent Nerv Syst Agents 2005; 5: 5-13.
22. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777-81.
23. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am 2005; 15: 727-53.
24. Zheng X, Zhou J, Xia Y. The role of TNF-alpha in regulating ketamine-induced hippocampal neurotoxicity. Arch Med Sci 2015; 10: 1296-302.
25. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-44.
26. Hellweg R, Wirth Y, Janetzky W, Hartmann S. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J Geriatr Psychiatry 2012; 27: 651-6.
27. Fa M, Orozco IJ, Francis YI, Saeed F, Gong Y, Arancio O. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. J Vis Exp 2010; 41: 1884.
28. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. Academic Press, Sydney 1986.
29. Jean YY, Baleriola J, Fà M, Hengst U, Troy CM. Stereotaxic infusion of oligomeric amyloid-beta into the mouse hippocampus. J Vis Exp 2015; 100: e52805.
30. Sun Y, Oberley LW, Li Y. Simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497-500.
31. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-69.
32. Jhoo JH, Kim HC, Nabeshima T, et al. Beta-amyloid (1–42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 2004; 155: 185-96.
33. Kim HC, Yamada K, Nitta A, et al. Immunocytochemical evidence that amyloid beta (1–42) impairs endogenous antioxidant systems in vivo. Neuroscience 2003; 119: 399-419.
34. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 2014; 76: 27-50.
35. Ugurluer G, Cebi A, Mert H, Mert N, Serin M, Erkal HS. Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study. Arch Med Sci 2016; 13: 1348-53.
36. Kertmen H, Gürer B, Yilmaz ER, et al. Antioxidant and antiapoptotic effects of darbepoetin-alpha against traumatic brain injury in rats. Arch Med Sci 2015; 11: 1119-28.
37. Prakash A, Kalra JK, Kumar A. Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats. J Basic Clin Physiol Pharmacol 2015; 26: 13-23.
38. Prakash A, Kumar A. Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer's disease. Neurotox Res 2014; 25: 335-47.
39. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci 2015; 11: 1164-78.
40. Celić E, Oguzturk H, Sahin N, Turtay MG, Oguz F, Ciftci O. Protective effects of hesperidin in experimental testicular ischemia/reperfusion injury in rats. Arch Med Sci 2016; 12: 928-34.